134 related articles for article (PubMed ID: 32641325)
21. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of Herceptin: a standard cost model for breast-cancer treatment in a Belgian university hospital.
Neyt MJ; Albrecht JA; Clarysse B; Cocquyt VF
Int J Technol Assess Health Care; 2005; 21(1):132-7. PubMed ID: 15736525
[TBL] [Abstract][Full Text] [Related]
23. Use of data-mining to support real-world cost analyses: An example using HER2-positive breast cancer in Iran.
Ansaripour A; Zendehdel K; Tadayon N; Sadeghi F; Uyl-de Groot CA; Redekop WK
PLoS One; 2018; 13(10):e0205079. PubMed ID: 30273393
[TBL] [Abstract][Full Text] [Related]
24. Development of a method to determine the cost of breast cancer treatment with chemotherapy at Groote Schuur Hospital, Cape Town, South Africa.
Guzha NT; Thebe T; Butler N; Valodia PN
S Afr Med J; 2020 Mar; 110(4):296-301. PubMed ID: 32657741
[TBL] [Abstract][Full Text] [Related]
25. Clinical and Pathological Characteristics of Triple Positive Breast Cancer among Iraqi Patients.
Alwan NAS; Mualla FH; Al Naqash M; Kathum S; Tawfiq FN; Nadhir S
Gulf J Oncolog; 2017 Sep; 1(25):51-60. PubMed ID: 29019331
[TBL] [Abstract][Full Text] [Related]
26. The effect of multidisciplinary heart failure clinic characteristics on 1-year postdischarge health care costs: a population-based study.
Wijeysundera HC; Austin PC; Wang X; Bennell MC; Abrahamyan L; Ko DT; Tu JV; Krahn M
Med Care; 2014 Mar; 52(3):272-9. PubMed ID: 24509362
[TBL] [Abstract][Full Text] [Related]
27. Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival.
Kobayashi N; Hikichi M; Ushimado K; Sugioka A; Kiriyama Y; Kuroda M; Utsumi T
Clin Transl Oncol; 2017 Oct; 19(10):1232-1240. PubMed ID: 28409323
[TBL] [Abstract][Full Text] [Related]
28. Breast-conserving therapy for triple-negative breast cancer.
Gangi A; Chung A; Mirocha J; Liou DZ; Leong T; Giuliano AE
JAMA Surg; 2014 Mar; 149(3):252-8. PubMed ID: 24382582
[TBL] [Abstract][Full Text] [Related]
29. The cost of medical care for patients with cystic fibrosis in a health maintenance organization.
Lieu TA; Ray GT; Farmer G; Shay GF
Pediatrics; 1999 Jun; 103(6):e72. PubMed ID: 10353969
[TBL] [Abstract][Full Text] [Related]
30. Improvement in COPD management by access to asthma/COPD clinics in primary care: data from the observational PATHOS study.
Lisspers K; Johansson G; Jansson C; Larsson K; Stratelis G; Hedegaard M; Ställberg B
Respir Med; 2014 Sep; 108(9):1345-54. PubMed ID: 25002194
[TBL] [Abstract][Full Text] [Related]
31. Time-driven activity-based costing to estimate cost of care at multidisciplinary aerodigestive centers.
Garcia JA; Mistry B; Hardy S; Fracchia MS; Hersh C; Wentland C; Vadakekalam J; Kaplan R; Hartnick CJ
Laryngoscope; 2017 Sep; 127(9):2152-2158. PubMed ID: 28635036
[TBL] [Abstract][Full Text] [Related]
32. Concordance with NCCN treatment guidelines: Relations with health care utilization, cost, and mortality in breast cancer patients with secondary metastasis.
Rocque GB; Williams CP; Kenzik KM; Jackson BE; Azuero A; Halilova KI; Ingram SA; Pisu M; Forero A; Bhatia S
Cancer; 2018 Nov; 124(21):4231-4240. PubMed ID: 30317547
[TBL] [Abstract][Full Text] [Related]
33. Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium.
Neyt M; Huybrechts M; Hulstaert F; Vrijens F; Ramaekers D
Health Policy; 2008 Aug; 87(2):146-59. PubMed ID: 18164510
[TBL] [Abstract][Full Text] [Related]
34. Variability of cost trajectories over the last year of life in patients with advanced breast cancer in the Netherlands.
Schneider PP; Pouwels XGLV; Passos VL; Ramaekers BLT; Geurts SME; Ibragimova KIE; de Boer M; Erdkamp F; Vriens BEPJ; van de Wouw AJ; den Boer MO; Pepels MJ; Tjan-Heijnen VCG; Joore MA
PLoS One; 2020; 15(4):e0230909. PubMed ID: 32271794
[TBL] [Abstract][Full Text] [Related]
35. Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. a single institution survey spanning 1998 to 2010.
García Fernández A; Giménez N; Fraile M; González S; Chabrera C; Torras M; González C; Salas A; Barco I; Cirera L; Cambra MJ; Veloso E; Pessarrodona A
Breast; 2012 Jun; 21(3):366-73. PubMed ID: 22487206
[TBL] [Abstract][Full Text] [Related]
36. Health system costs of metastatic breast cancer.
Wai ES; Trevisan CH; Taylor SCM ; Mates D; Jackson JS; Olivotto IA
Breast Cancer Res Treat; 2001 Feb; 65(3):233-40. PubMed ID: 11336245
[TBL] [Abstract][Full Text] [Related]
37. Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival.
Lee JA; Kim KI; Bae JW; Jung YH; An H; Lee ES;
Breast Cancer Res Treat; 2010 Aug; 123(1):177-87. PubMed ID: 20574671
[TBL] [Abstract][Full Text] [Related]
38. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
[TBL] [Abstract][Full Text] [Related]
39. Economic burden of diverticular disease: An observational analysis based on real world data from an Italian region.
Mennini FS; Sciattella P; Marcellusi A; Toraldo B; Koch M
Dig Liver Dis; 2017 Sep; 49(9):1003-1008. PubMed ID: 28663067
[TBL] [Abstract][Full Text] [Related]
40. Health economic burden of patients with restless legs syndrome in a German ambulatory setting.
Dodel R; Happe S; Peglau I; Mayer G; Wasem J; Reese JP; Giani G; Geraedts M; Trenkwalder C; Oertel WH; Stiasny-Kolster K
Pharmacoeconomics; 2010; 28(5):381-93. PubMed ID: 20297866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
